Korean J Gastroenterol.  2016 Feb;67(2):64-73. 10.4166/kjg.2016.67.2.64.

Golimumab Therapy in Ulcerative Colitis

Affiliations
  • 1Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. moonone70@hanmail.net

Abstract

Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-alpha) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-alpha agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis.

Keyword

Ulcerative colitis; Tumor necrosis factor-alpha; Infliximab; Adalimumab; Golimumab
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr